Cargando…
Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study
BACKGROUND: Health care-associated urinary tract infection (HAUTI) consists of unique conditions (cystitis, pyelonephritis and urosepsis). These conditions could have different pathogen diversity and antibiotic resistance impacting on the empirical antibiotic choices. The aim of this study is to com...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954147/ https://www.ncbi.nlm.nih.gov/pubmed/31555835 http://dx.doi.org/10.1007/s00345-019-02963-9 |
_version_ | 1783486748687335424 |
---|---|
author | Tandogdu, Zafer Koves, Bela Cai, Tommaso Cek, Mete Tenke, Peter Naber, Kurt Wagenlehner, Florian Johansen, Truls Erik Bjerklund |
author_facet | Tandogdu, Zafer Koves, Bela Cai, Tommaso Cek, Mete Tenke, Peter Naber, Kurt Wagenlehner, Florian Johansen, Truls Erik Bjerklund |
author_sort | Tandogdu, Zafer |
collection | PubMed |
description | BACKGROUND: Health care-associated urinary tract infection (HAUTI) consists of unique conditions (cystitis, pyelonephritis and urosepsis). These conditions could have different pathogen diversity and antibiotic resistance impacting on the empirical antibiotic choices. The aim of this study is to compare the estimated chances of coverage of empirical antibiotics between conditions (cystitis, pyelonephritis and urosepsis) in urology departments from Europe. METHODS: A mathematical modelling based on antibiotic susceptibility data from a point prevalence study was carried. Data were obtained for HAUTI patients from multiple urology departments in Europe from 2006 to 2017. The primary outcome of the study is the Bayesian weighted incidence syndromic antibiogram (WISCA) and Bayesian factor. Bayesian WISCA is the estimated chance of an antibiotic to cover the causative pathogens when used for first-line empirical treatment. Bayesian factor is used to compare if HAUTI conditions did or did not impact on empirical antibiotic choices. RESULTS: Bayesian WISCA of antibiotics in European urology departments from 2006 to 2017 ranged between 0.07 (cystitis, 2006, Amoxicillin) to 0.89 (pyelonephritis, 2009, Imipenem). Bayesian WISCA estimates were lowest in urosepsis. Clinical infective conditions had an impact on the Bayesian WISCA estimates (Bayesian factor > 3 in 81% of studied antibiotics). The main limitation of the study is the lack of local data. CONCLUSIONS: Our estimates illustrate that antibiotic choices can be different between HAUTI conditions. Findings can improve empirical antibiotic selection towards a personalized approach but should be validated in local surveillance studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00345-019-02963-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6954147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-69541472020-01-23 Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study Tandogdu, Zafer Koves, Bela Cai, Tommaso Cek, Mete Tenke, Peter Naber, Kurt Wagenlehner, Florian Johansen, Truls Erik Bjerklund World J Urol Topic Paper BACKGROUND: Health care-associated urinary tract infection (HAUTI) consists of unique conditions (cystitis, pyelonephritis and urosepsis). These conditions could have different pathogen diversity and antibiotic resistance impacting on the empirical antibiotic choices. The aim of this study is to compare the estimated chances of coverage of empirical antibiotics between conditions (cystitis, pyelonephritis and urosepsis) in urology departments from Europe. METHODS: A mathematical modelling based on antibiotic susceptibility data from a point prevalence study was carried. Data were obtained for HAUTI patients from multiple urology departments in Europe from 2006 to 2017. The primary outcome of the study is the Bayesian weighted incidence syndromic antibiogram (WISCA) and Bayesian factor. Bayesian WISCA is the estimated chance of an antibiotic to cover the causative pathogens when used for first-line empirical treatment. Bayesian factor is used to compare if HAUTI conditions did or did not impact on empirical antibiotic choices. RESULTS: Bayesian WISCA of antibiotics in European urology departments from 2006 to 2017 ranged between 0.07 (cystitis, 2006, Amoxicillin) to 0.89 (pyelonephritis, 2009, Imipenem). Bayesian WISCA estimates were lowest in urosepsis. Clinical infective conditions had an impact on the Bayesian WISCA estimates (Bayesian factor > 3 in 81% of studied antibiotics). The main limitation of the study is the lack of local data. CONCLUSIONS: Our estimates illustrate that antibiotic choices can be different between HAUTI conditions. Findings can improve empirical antibiotic selection towards a personalized approach but should be validated in local surveillance studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00345-019-02963-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-09-25 2020 /pmc/articles/PMC6954147/ /pubmed/31555835 http://dx.doi.org/10.1007/s00345-019-02963-9 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Topic Paper Tandogdu, Zafer Koves, Bela Cai, Tommaso Cek, Mete Tenke, Peter Naber, Kurt Wagenlehner, Florian Johansen, Truls Erik Bjerklund Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study |
title | Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study |
title_full | Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study |
title_fullStr | Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study |
title_full_unstemmed | Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study |
title_short | Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study |
title_sort | condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study |
topic | Topic Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954147/ https://www.ncbi.nlm.nih.gov/pubmed/31555835 http://dx.doi.org/10.1007/s00345-019-02963-9 |
work_keys_str_mv | AT tandogduzafer conditionspecificsurveillanceinhealthcareassociatedurinarytractinfectionsasastrategytoimproveempiricalantibiotictreatmentanepidemiologicalmodellingstudy AT kovesbela conditionspecificsurveillanceinhealthcareassociatedurinarytractinfectionsasastrategytoimproveempiricalantibiotictreatmentanepidemiologicalmodellingstudy AT caitommaso conditionspecificsurveillanceinhealthcareassociatedurinarytractinfectionsasastrategytoimproveempiricalantibiotictreatmentanepidemiologicalmodellingstudy AT cekmete conditionspecificsurveillanceinhealthcareassociatedurinarytractinfectionsasastrategytoimproveempiricalantibiotictreatmentanepidemiologicalmodellingstudy AT tenkepeter conditionspecificsurveillanceinhealthcareassociatedurinarytractinfectionsasastrategytoimproveempiricalantibiotictreatmentanepidemiologicalmodellingstudy AT naberkurt conditionspecificsurveillanceinhealthcareassociatedurinarytractinfectionsasastrategytoimproveempiricalantibiotictreatmentanepidemiologicalmodellingstudy AT wagenlehnerflorian conditionspecificsurveillanceinhealthcareassociatedurinarytractinfectionsasastrategytoimproveempiricalantibiotictreatmentanepidemiologicalmodellingstudy AT johansentrulserikbjerklund conditionspecificsurveillanceinhealthcareassociatedurinarytractinfectionsasastrategytoimproveempiricalantibiotictreatmentanepidemiologicalmodellingstudy |